Antares Pharma Welcomes Marvin Samson to Board of Directors
May 23 2013 - 7:00AM
Business Wire
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the election
of Marvin Samson to the Company’s Board of Directors.
Mr. Samson is an expert in injectable manufacturing and delivery
systems. He was formerly Group Vice President – Worldwide
Injectables of Teva, previously having served as Chief Executive
Officer and a member of the Board of Directors of Sicor. He was
also a founder and CEO of Elkins-Sinn, Inc. and Marsam
Pharmaceuticals.
Leonard S. Jacob, M.D., Ph.D., Chairman of the Board of Antares
Pharma, stated, “I have been an industry colleague of Marvin Samson
for many years. His broad expertise in all aspects of our business
will be an important asset to us as we prepare to launch OTREXUP™
early next year. I look forward to the perspective and insight he
will bring to our Company.”
“I have observed the rapid growth of Antares Pharma over the
past few years, and I am excited about joining the Antares Board,”
said Marvin Samson. “The use of drug/device combinations is very
innovative, and I look forward to helping the Company as they
prepare to launch OTREXUP™ followed by the Quick Shot testosterone
product.”
Mr. Samson was elected by shareholders at yesterday’s 2013
Annual Meeting of Stockholders. In addition to his work at
Elkins-Sinn and Marsam Pharmaceuticals, he is the founder and CEO
of Samson Medical Technologies, a privately held company providing
hospital and alternate site pharmacists with injectable drug
delivery systems and programs. Mr. Samson is Chairman of the
University Of Sciences Board Of Trustees. He is also Chairman of
the Board of JHP Pharmaceuticals and serves on the Board of
Directors of Flynn Pharma, NanoPass Technologies Ltd and Emcure
Pharmaceuticals Ltd. Additionally, Mr. Samson served as Chairman of
the Board and CEO of Qualitest Pharmaceuticals prior to its
purchase by Endo Pharmaceuticals in late 2010 and as the Chairman
of the Generic Pharmaceutical Industry Association from 1997 to
2000. Mr. Samson is the holder of five U.S. patents pertaining to
pharmaceutical manufacturing. Mr. Samson graduated from Temple
University with a B.S. in Chemistry.
Paul K. Wotton, Ph.D., President and Chief Executive Officer,
stated, “We are very fortunate to have someone of Marvin’s
background and experience join the Board of Directors of Antares.
His extensive commercial expertise in injectable manufacturing and
delivery systems will be invaluable as we launch new products and
add to an already exciting pipeline.”
About Antares Pharma
Antares Pharma focuses on self-administered parenteral
pharmaceutical products and topical gel-based medicines. The
Company is developing OTREXUP™, a combination product for the
delivery of methotrexate using Medi-Jet™ technology for the
treatment of rheumatoid arthritis, poly-articular-course juvenile
rheumatoid arthritis and psoriasis, as well as VIBEX™ QS T for
testosterone replacement therapy. The Company's technology
platforms include VIBEX™ disposable Medi-Jet™, disposable multi-use
pen injectors and Vision™ reusable needle-free injectors marketed
as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva)
and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma
has a multi-product deal with Teva that includes Tev-Tropin® human
growth hormone (hGH), VIBEX™ epinephrine and several other
products. Antares Pharma’s partnership with Ferring includes
Zomacton® hGH. In the U.S. Antares has received FDA approval for
Gelnique 3%™, a treatment for overactive bladder that is marketed
by Actavis. Elestrin® (estradiol gel) is FDA approved for the
treatment of moderate-to-severe vasomotor symptoms associated with
menopause, and is marketed in the U.S. by Meda Pharma. Antares
Pharma has two facilities in the U.S. The Parenteral Products Group
located in Minneapolis, Minnesota directs the manufacturing and
marketing of the Company’s reusable needle-free injection devices
and related disposables, and develops its disposable
pressure-assisted Medi-Jet and pen injector systems. The Company’s
corporate office and Product Development and Commercial Groups are
located in Ewing, New Jersey.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These statements are indicated by
the words “may,” “will,” “plans,” “intends,” “believes,” “expects,”
“anticipates,” “potential,” “could,” “would,” “should,” and similar
expressions. Such forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that
may cause actual results to differ materially from those
anticipated by the forward-looking statements. These risks and
uncertainties include, among others, changes in revenue growth and
difficulties or delays in the initiation, progress, or completion
of product development. In addition, the OTREXUP™ and Quick Shot
testosterone products referred to in this press release have not
yet been approved by the FDA, and the commercialization of OTREXUP™
and Quick Shot testosterone are dependent on the Company receiving
FDA approval of these products. Additional information concerning
these and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2012, and in
the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions investors
not to place undue reliance on the forward-looking statements
contained in this press release. All forward-looking statements are
based on information currently available to the Company on the date
hereof, and the Company undertakes no obligation to revise or
update these forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by law.
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024